Fig. 1: Therapeutic treatment with Siglec-8 mAb reduces CS-induced airway inflammation and improves lung function in experimental COPD. | Mucosal Immunology

Fig. 1: Therapeutic treatment with Siglec-8 mAb reduces CS-induced airway inflammation and improves lung function in experimental COPD.

From: A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation

Fig. 1

a Schematic of experimental COPD model. b Total leukocytes, c neutrophils, d lymphocytes, e CXCL1 levels, f and CCL2 levels in BAL fluid from mice exposed to normal air (black), ISO + smoke (gray) or anti-S8 + smoke (blue). Enumeration of g absolute lung MCs and h degranulating MCs by chloroacetate esterase staining, and i quantification of MCPT1 in serum of mice exposed to normal air (black), ISO + smoke (gray) or anti-S8 + smoke (blue). j, k Total histopathology score in lung sections or specifically in the airways. l, m Total lung capacity and tissue elastance lung function parameters. Data are plotted as mean ± SEM (6–8 mice/group) *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 by one-way ANOVA with Tukey’s multiple-comparisons test. BAL bronchoalveolar lavage, q7D dosed every 7 days, COPD chronic obstructive pulmonary disease, MCPT mast cell protease, TLC total lung capacity, ISO isotype control.

Back to article page